Dynamic comparison between Daan real-time PCR and Cobas TaqMan for quantification of HBV DNA levels in patients with CHB

• Published in: BMC infectious diseases 2014-02, Vol.14 (1), p.85-85, Article 85
• Main Authors: Cai, Shao-hang, Lv, Fang-fang, Zhang, Yong-hong, Jiang, Ye-gui, Peng, Jie
• Format: Article
• Language: English
• Subjects: Adenine - analogs & derivatives; Adenine - therapeutic use; Adolescent; Adult; Antiviral Agents - therapeutic use; DNA, Viral - blood; Drug therapy; Female; Guanine - analogs & derivatives; Guanine - therapeutic use; Hepatitis; Hepatitis B virus; Hepatitis B, Chronic - virology; HIV; Human immunodeficiency virus; Humans; Lamivudine - therapeutic use; Liver cirrhosis; Male; Middle Aged; Organophosphonates - therapeutic use; Polymerase chain reaction; Polymerase Chain Reaction - methods; Prospective Studies; Real-Time Polymerase Chain Reaction - methods; Reproducibility of Results; Sensitivity and Specificity; Viral Load; Young Adult
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/1471-2334-14-85

Hepatitis B virus (HBV) DNA levels are crucial for managing chronic hepatitis B (CHB). It was unclear whether Daan real-time polymerase chain reaction test (Daan test) or COBAS TaqMan HBV DNA Test (Cobas TaqMan) was superior in measuring different HBV DNA levels in clinical specimens. We enrolled 67 treatment-naïve, HBV surface antigen-positive CHB patients (high baseline viral levels) who received either lamivudine/adefovir or entecavir. Serum samples were tested at baseline and treatment week 24 using the Daan test and Cobas TaqMan. In the 67-baseline samples, the HBV DNA levels with the Cobas TaqMan (7.90 ± 0.73 log10 IU/mL) were significantly greater than those of the Daan test (7.11 ± 0.44 log10 IU/mL; P